Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer... Show more
GMAB's Aroon Indicator triggered a bullish signal on June 24, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 213 similar instances where the Aroon Indicator showed a similar pattern. In of the 213 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for GMAB crossed bullishly above the 50-day moving average on May 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in of 330 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for GMAB moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GMAB as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GMAB turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
GMAB moved below its 50-day moving average on June 23, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GMAB broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.388) is normal, around the industry mean (16.539). P/E Ratio (12.041) is within average values for comparable stocks, (59.016). Projected Growth (PEG Ratio) (1.079) is also within normal values, averaging (2.300). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (4.235) is also within normal values, averaging (255.605).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.
Industry Biotechnology
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.
Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
---|---|---|---|---|
GMAB | 100% | -1.06% | ||
GNMSF - GMAB | 58% Loosely correlated | N/A | ||
AXON - GMAB | 47% Loosely correlated | -1.16% | ||
ARVN - GMAB | 38% Loosely correlated | +0.78% | ||
ARGX - GMAB | 38% Loosely correlated | -1.33% | ||
TECH - GMAB | 37% Loosely correlated | +3.78% | ||
More |